These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 34592886)
41. Heat shock factor 5 correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. Aizemaiti R; Wu Z; Tang J; Yan H; Lv X Int J Med Sci; 2021; 18(2):448-458. PubMed ID: 33390814 [TBL] [Abstract][Full Text] [Related]
42. Significance of Lin H; Wang J; Shi Q; Wu M PeerJ; 2024; 12():e17338. PubMed ID: 38708353 [TBL] [Abstract][Full Text] [Related]
43. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma. Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085 [No Abstract] [Full Text] [Related]
44. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma. Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904 [TBL] [Abstract][Full Text] [Related]
45. Junctional Adhesion Molecule-Like Protein (JAML) Is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma. Fang L; Yu W; Yu G; Zhong F; Ye B Med Sci Monit; 2022 Jan; 28():e933503. PubMed ID: 35034089 [TBL] [Abstract][Full Text] [Related]
46. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. Xu XL; Gong Y; Zhao DP Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913 [TBL] [Abstract][Full Text] [Related]
47. Unveiling the Enigmatic Role of SLC35F3 in Lung Adenocarcinoma. Ye Y; Long F; Yue W; Wei Z; Yang J; Xie Y Clin Respir J; 2024 Oct; 18(10):e70023. PubMed ID: 39414367 [TBL] [Abstract][Full Text] [Related]
48. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models. Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990 [TBL] [Abstract][Full Text] [Related]
49. Consensus clustering and novel risk score model construction based on m6A methylation regulators to evaluate the prognosis and tumor immune microenvironment of early-stage lung adenocarcinoma. He M; Zhi Y; Li C; Zhao C; Yang G; Lv J; You H; Huang H; Cao X Aging (Albany NY); 2024 Jul; 16(14):11318-11338. PubMed ID: 39028290 [TBL] [Abstract][Full Text] [Related]
50. P3H4 Overexpression Serves as a Prognostic Factor in Lung Adenocarcinoma. Jin X; Zhou H; Song J; Cui H; Luo Y; Jiang H Comput Math Methods Med; 2021; 2021():9971353. PubMed ID: 34257701 [TBL] [Abstract][Full Text] [Related]
51. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma. Yu Y; Wang Z; Zheng Q; Li J Gene; 2021 Jul; 790():145689. PubMed ID: 33964375 [TBL] [Abstract][Full Text] [Related]
52. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation. Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526 [TBL] [Abstract][Full Text] [Related]
53. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573 [TBL] [Abstract][Full Text] [Related]
54. Prognostic value and molecular mechanisms of OAS1 in lung adenocarcinoma. Wang L; Gao L; Ding F; Gao K; Liu Q; Yin X BMC Pulm Med; 2024 Sep; 24(1):473. PubMed ID: 39334033 [TBL] [Abstract][Full Text] [Related]
55. Identification of potential diagnostic and prognostic biomarkers for LUAD based on TCGA and GEO databases. Zheng Q; Min S; Zhou Q Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34017995 [TBL] [Abstract][Full Text] [Related]
56. Advanced Glycation End Products' Receptor DNA Methylation Associated with Immune Infiltration and Prognosis of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Yang J; Lin M; Zhang M; Wang Z; Lin H; Yu Y; Zheng Q; Chen X; Wu Y; Yao Q; Li J Genet Res (Camb); 2023; 2023():7129325. PubMed ID: 37497166 [TBL] [Abstract][Full Text] [Related]
57. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
58. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma. Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451 [TBL] [Abstract][Full Text] [Related]
59. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. Fan K; Zhang BH; Han D; Sun YC BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494 [TBL] [Abstract][Full Text] [Related]
60. Identification and prognostic biomarkers among ZDHHC4/12/18/24, and APT2 in lung adenocarcinoma. Bian J; Xiong W; Yang Z; Li M; Song D; Zhang Y; Liu C Sci Rep; 2024 Jan; 14(1):522. PubMed ID: 38177255 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]